These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 7986711)

  • 21. Defects of beta 2-adrenergic signal transduction in chronic lymphocytic leukaemia: relationship to disease progression.
    Kamp T; Liebl B; Haen E; Emmerich B; Hallek M
    Eur J Clin Invest; 1997 Feb; 27(2):121-7. PubMed ID: 9061305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-beta-arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro.
    Begleiter A; Verburg L; Ashique A; Lee K; Israels LG; Mowat MR; Johnston JB
    Leukemia; 1995 Nov; 9(11):1875-81. PubMed ID: 7475278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report.
    Ahmad I; Al-Katib AM; Beck FW; Mohammad RM
    Clin Cancer Res; 2000 Apr; 6(4):1328-32. PubMed ID: 10778958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hairy cell leukemia and its treatment with 2-chlorodeoxyadenosine (2-CdA)].
    Pawelski S
    Acta Haematol Pol; 1995; 26(2):139-43. PubMed ID: 7653218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia and chronic lymphocytic leukemia.
    Saven A; Piro LD
    Leuk Lymphoma; 1993; 11 Suppl 2():109-14. PubMed ID: 7907251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Similarities between the sensitivity to 2-chlorodeoxyadenosine of lymphocytes from CLL patients and bryostatin 1-treated WSU-CLL cells: an infrared spectroscopic study.
    Liu KZ; Schultz CP; Mohammad RM; Al-Katib AM; Johnston JB; Mantsch HH
    Cancer Lett; 1998 May; 127(1-2):185-93. PubMed ID: 9619876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hairy cell leukemia therapy by cladribine].
    Ogura M
    Nihon Rinsho; 2004 Jul; 62(7):1337-42. PubMed ID: 15283153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.
    Robak T; Wierzbowska A; Błasińska-Morawiec M; Korycka A; Błoński JZ
    Mediators Inflamm; 1999; 8(6):277-86. PubMed ID: 10815616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
    Jehn U; Bartl R; Dietzfelbinger H; Haferlach T; Heinemann V
    Leukemia; 2004 Sep; 18(9):1476-81. PubMed ID: 15229616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hairy cell leukemia and allied chronic lymphoid leukemias: current knowledge and new therapeutic options.
    Polliack A
    Leuk Lymphoma; 1997 Dec; 26 Suppl 1():41-51. PubMed ID: 9570679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
    Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
    Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. On the phosphorylation of 2-chlorodeoxyadenosine (CdA) and its correlation with clinical response in leukemia treatment.
    Arnér ES
    Leuk Lymphoma; 1996 Apr; 21(3-4):225-31. PubMed ID: 8726403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bryostatin 1-induced modulation of nucleoside transporters and 2-chlorodeoxyadenosine influx in WSU-CLL cells.
    Beck FW; Al-Katib AM; Ahmad I; Wall NR; Liu KZ; Mantsch HH; Mohammad RM
    Int J Mol Med; 2000 Apr; 5(4):341-7. PubMed ID: 10719048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of chronic lymphoid leukaemias according to FAB.
    Oertel J; Kastner M; Bai AR; Kleiner S; Huhn D
    Leuk Res; 1992 Sep; 16(9):919-27. PubMed ID: 1405721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hairy cell leukemia: results of 2-chlorodeoxyadenosine therapy in Jerusalem.
    Dann EJ; Gillis S; Rachmilewitz EA; Barak V; Cass Y; Ruchlemer R; Polliack A
    Leuk Lymphoma; 1994; 14 Suppl 1():127-31. PubMed ID: 7820044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia.
    Albertioni F; Lindemalm S; Reichelova V; Pettersson B; Eriksson S; Juliusson G; Liliemark J
    Clin Cancer Res; 1998 Mar; 4(3):653-8. PubMed ID: 9533533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Subcutaneous therapy of hairy cell leukemia with 2-chlorodeoxyadenosine].
    Nielsen OJ; Hippe E; Priø TK; Juliusson G
    Ugeskr Laeger; 1994 Apr; 156(16):2407-9. PubMed ID: 7912015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II clinical study of cladribine in the treatment of hairy cell leukemia.
    Machii T; Chou T; Suzuki M; Ohe Y; Katagiri S; Kitano EK; Kitano K; Fujiyama Y; Izumi T; Shimazaki C; Nanba K; Ohashi Y; Kitani T;
    Int J Hematol; 2005 Oct; 82(3):230-5. PubMed ID: 16207596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of cytotoxicity of 2-chloro- 2'-arabino-fluoro-2'-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia.
    Lindemalm S; Liliemark J; Gruber A; Eriksson S; Karlsson MO; Wang Y; Albertioni F
    Haematologica; 2003 Mar; 88(3):324-32. PubMed ID: 12651272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia.
    Lindemalm S; Liliemark J; Juliusson G; Larsson R; Albertioni F
    Cancer Lett; 2004 Jul; 210(2):171-7. PubMed ID: 15183532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.